Coronavirus Notebook: WHO Backs MAb Combo, EMA Assessing Moderna Booster Jab
The COVID Moonshot project has received new funding for the open-source development of new candidate therapeutics, with results expected by the end of the year.
You may also be interested in...
Coronavirus Notebook: Sanofi Under Pressure To Hand mRNA Vaccine To Africa, EMA OKs Booster Dose For Comirnaty
The European Medicines Agency says there is a possible link between the Janssen vaccine and rare cases of venous thromboembolism, and that immune thrombocytopenia should be added as an adverse reaction to the Janssen and AstraZeneca vaccines. The agency has also begun evaluating a marketing authorization application for Celltrion’s regdanvimab in COVID-19 patients.
Nearly 70% of the FDA workforce would be retained, most from carryover user fee dollars, but potential morale problems loom if government funding runs out again.
The European Medicines Agency also expects to reach some conclusions on the use of MAb-based COVID-19 treatments by the end of October.